Product Information
LAMICTAL XR 300 MG TABLET is a brand product labeled by GlaxoSmithKline LLC, priced at $48.6328 per EA under NDC 00173076100. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on May 29, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the lamotrigine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
GlaxoSmithKline LLCNDC
00173076100
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
LAMOTRIGINEApproval Type
New Drug (NDA)
FDA Application
NDA022115FDA Approved
5/29/2009
TE Code
AB
On Market Since
3/31/2011
Pharmacological Classes
Price Statistics
The NADAC for LAMICTAL XR 300 MG TABLET has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 144.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $48.6328 per EA |
|---|---|
| All-time high | $48.8723 (Jun 10, 2026) |
| All-time low | $19.9216 (Nov 28, 2013) |
| 52-week high | $48.8723 |
| 52-week low | $47.3950 |
| Median price | $37.8963 |
| Average price | $37.5721 |
| Largest weekly change | +15.0% (Dec 30, 2015) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lamotrigine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LAMICTAL XR 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMICTAL XR 300 MG TABLET, manufactured by GlaxoSmithKline LLC, is $48.6328 per EA (NDC 00173076100), effective Aug 19, 2026.
How has the price of LAMICTAL XR 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for LAMICTAL XR 300 MG TABLET has risen 144.1%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LAMICTAL XR 300 MG TABLET?
Since Nov 28, 2013, the NADAC for LAMICTAL XR 300 MG TABLET has ranged from a low of $19.9216 (Nov 28, 2013) to a high of $48.8723 (Jun 10, 2026), with a median of $37.8963 per EA.
Are there cheaper alternatives to LAMICTAL XR 300 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LAMICTAL XR 300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LAMICTAL XR 300 MG TABLET?
LAMICTAL XR 300 MG TABLET (NDC 00173076100) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.